Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Annovis Bio Inc. (ANVS)

13.04   -0.49 (-3.62%) 01-21 18:33
Open: 13.43 Pre. Close: 13.53
High: 13.66 Low: 12.96
Volume: 128,882 Market Cap: 106M
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is ANVS401, which is in Phase 2a clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, Alzheimer's disease in Down Syndrome, and other chronic neurodegenerative disorders. It is also developing ANVS405 for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 13.68 - 13.776 13.776 - 13.849
Low: 12.717 - 12.843 12.843 - 12.94
Close: 12.866 - 13.036 13.036 - 13.167

Technical analysis

as of: 2022-01-21 4:24:45 PM
Overall:       
Stoxline posted a SELL today, upgraded from strong sell. Downward movement continues, but could change at any time.
Target: Six months: 21.65     One year: 25.67
Support: Support1: 12.96    Support2: 10.78
Resistance: Resistance1: 18.53    Resistance2: 21.98
Pivot: 16.27
Moving Average: MA(5): 14.10     MA(20): 16.98
MA(100): 26.16     MA(250): 38.54
MACD: MACD(12,26): -2.12     Signal(9): -1.92
Stochastic oscillator: %K(14,3): 1.65     %D(3): 4.19
RSI: RSI(14): 27.26
52-week: High: 132.00  Low: 9.71  Change(%): 31.1
Average Vol(K): 3-Month: 164  10-Days: 97

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and BEARISH in mid-long term.
ANVS has closed above bottom band by 6.9%. Bollinger Bands are 7.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Wed, 19 Jan 2022
Insiders might want to re-evaluate their US$658k stock purchase as Annovis Bio, Inc. (NYSE:ANVS) drops to US$117m - Nasdaq

Mon, 10 Jan 2022
Annovis Bio Enhances Leadership Team with Two Senior Appointments - Yahoo Finance

Wed, 05 Jan 2022
Annovis Bio Announces Official Unique Name Buntanetap for Lead Candidate ANVS401 - The Kingston Whig-Standard

Mon, 03 Jan 2022
Annovis Bio to Participate in the Biotech Showcase and H.C. Wainwright Bioconnect Virtual Conferences - Yahoo Finance

Thu, 30 Dec 2021
What You Need To Know About Annovis Bio, Inc.'s (NYSE:ANVS) Investor Composition - Simply Wall St

Mon, 20 Dec 2021
Annovis Bio CEO Maria Maccecchini Issues Letter to Stockholders - Yahoo Finance

Financial Analysis

Growth n/a
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability n/a
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency n/a
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency n/a
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Price to Book Value: Outperform Discounted cash flow: Outperform
Return on Assets: Neutral Price to Earnings: Underperform
Return on Equity: Neutral Debt to Equity: Neutral
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  AMEX
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 8
Shares Float (M) 6
% Held by Insiders 31.05
% Held by Institutions 18.55
Shares Short (K) 394
Shares Short P. Month (K) 458

Stock Financials

EPS -1.400
EPS Est This Year
EPS Est Next Year
Book Value (p.s.) 5.740
Profit Margin
Operating Margin
Return on Assets (ttm) -23.1
Return on Equity (ttm) -36.9
Qtrly Rev. Growth
Gross Profit (p.s.)
Sales Per Share
EBITDA (p.s.)
Qtrly Earnings Growth
Operating Cash Flow (M) -8
Levered Free Cash Flow (M) -4

Stock Valuations

PE Ratio -9.31
PEG Ratio
Price to Book value 2.27
Price to Sales
Price to Cash Flow

Stock Dividends

Dividend
Forward Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
android_stock_chart
Stock Chart
stoxline_lite
Stoxline Lite
stoxline_pro
Stoxline Pro
Option_Calculator
Option Calculator
(c) 2006-2020 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.